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Abstract The second edition of the International Classi-
ﬁcation of Headache Disorders makes a distinction between
primary and secondary headaches. The diagnosis of a sec-
ondaryheadacheismadeiftheunderlyingdiseaseisthought
to cause headache or if a close temporal relationship is
presenttogetherwiththeoccurrenceoftheheadache.Atﬁrst
glance, this may allow clearly secondary headaches to be
distinguished from primary headaches. However, by
reviewing the available literature concerning several selec-
ted secondary headaches,we willdiscussthehypothesisthat
some secondary headaches can also be understood as a var-
iation of primary headaches in the sense that the underlying
cause (e.g. infusion of glyceryl trinitrate [ICHD-II 8.1.1],
epilepsy [7.6.2], brain tumours [7.4], craniotomy [5.7], etc.)
triggers the same neurophysiologic mechanisms that are
responsible for the pain in primary headache attacks.
Keywords Secondary headache  Primary headache 
Headache triggers  GTN  Epilepsy  Brain tumour 
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Introduction
In the second edition of the International Classiﬁcation of
Headache Disorders (IHCD-II), the International Headache
Society (IHS) makes a strict distinction between primary and
secondary headaches [1]. The secondary headaches are
‘attributed to’ another disorder since ‘the causallink between
the underlying disorder and the headache is in most cases
well-established’. A broad range of different disorders is
accepted to be causative for headaches and includes head or
neck trauma (e.g. post-craniotomy headache: ICHD-II code
5.7), vascular disorders (e.g. non-traumatic intracranial intra-
cerebral haemorrhage ICHD-II 6.2), intracranial neoplasms
(ICHD-II 7.4), epileptic seizures (ICHD-II 7.6), acute sub-
stance use (ICHD-II 8.1), and intracranial infection (ICHD-II
9.1). Furthermore, a secondary headache can only be diag-
nosed with certainty if the headache resolves after elimination
of the cause. In real life, however, such a causal relationship
cannot always be established and the headache can become
chronic even when the underlying cause is resolved (e.g.
posttraumatic headache after minor head trauma).
According to the ICHD-II, one of the main conse-
quences of the rigorous separation is that the classiﬁcation
and diagnostic criteria differ in that they are aetiological
for secondary headaches and symptom based for primary
headaches. The following constellations are possible:
1. A new headache occurs together with another disorder
that is known to cause headache. This headache is
coded as a secondary headache independent of the
clinical phenotype.
2. If a pre-existing headache is worsened during the
occurrence of another disorder that is known to cause
headache, it has to be decided whether the patient is
given the diagnosis of the pre-existing headache or the
diagnosis of both the primary headache and a second-
ary headache. Factors in favour of a secondary
headache are (i) a close temporal relationship between
headache worsening and the manifestation of the
probable causative disorder, (ii) a signiﬁcant worsen-
ing, (iii) evidence that the disorder can aggravate the
primary headache and (iv) improvement of the head-
ache after relief of the causative disorder.
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diagnosed if the additional disorder can cause headache or
if certain associations are present between the additional
disorder and the headache. Otherwise, the primary disorder
is diagnosed. This division in secondary and primary
headaches in the ICHD-II has proven great practicality and
it was an important step in the understanding of headache.
However, a third constellation is possible, namely, that a
secondary headache is actually a variation of the primary
headache in the sense that the underlying brain disorder
(e.g. trauma, tumour, vascular disorder, inﬂammation, etc.)
triggers the same mechanisms that are also responsible for
primary headache attacks.
In recent years, there has been growing evidence in
support of such a diversiﬁcation of the term ‘secondary
headache’. Finally, there is also increasing knowledge
about the pathophysiology of primary headaches, which
might make the distinction between primary and secondary
headaches questionable. For example, there is a broad
discussion about whether cerebral microembolism can
trigger migraine attacks [2]. In this case, should the head-
ache be classiﬁed as primary headache or as secondary
headache? The boundaries between a subgroup of sec-
ondary headaches and the primary headaches seem to
become indistinct and studying secondary headaches might
even be informative for the understanding of primary
headaches. In this article, we aim to review recent ﬁndings
on the mechanisms of a selection of so-called secondary
headaches to demonstrate such an interrelationship
between primary and secondary headaches. Our selection
of secondary headaches represents a proportion of all
secondary headaches. They were chosen based on their
importance on the understanding of the pathophysiology of
primary and secondary headaches (headache in patients
after acute substance use) and based on our personal
experience. It was not our intention to give a complete
overview of all secondary headaches.
Selected so-called ‘secondary headaches’
Headache in patients after acute substance use:
after exposure to glyceryl trinitrate (GTN)
Migraine It has been known for over a century that nitro-
glycerine causes typical headaches, e.g. in munitions
workers [3]. In the late 1980s and 1990s, the group of
Olesen and Iversen from the Danish Headache Center
studied this in detail using an infusion of glyceryl trinitrate
(GTN) as a human model of migraine [4, 5]. Based on that
work, the ICHD-II distinguishes between an immediate
headache during GTN-infusion (ICHD-II 8.1.1.1) and a
delayed form (ICHD-II 8.1.1.2). In a double-blind,
placebo-controlled, crossover study of migraineurs, the
delayed headache occurred only after GTN-infusion and
fulﬁlled the criteria for migraine without aura in eight of
ten patients [6]. Even patients with migraine with aura
usually do not experience an aura [7], although rare
exceptions have been published [8]. This suggests that
GTN cannot induce an aura but can trigger migraine
attacks. The tendency to develop headache after GTN was
independent of the background frequency of migraine
attacks per month [9]. Besides head pain, sensitivity to
light or sound and some vegetative features, such as nau-
sea, migraine is characterised by additional central nervous
system symptoms, including neck stiffness, concentration
problems, tiredness, irritability and craving [10]. Some of
these occur even prior to the headache and are recognised
by patients as predictive premonitory symptoms. Interest-
ingly, migraine patients notice the same symptoms prior to
a delayed headache after triggering with GTN [8]. This
study further demonstrated that even the laterality of the
GTN-triggered headache was identical to the usual head-
ache in 28 of 30 study participants.
Weiller et al. [11] have done one of the key paraclin-
ical studies in migraine. They showed an activation of the
brain stem in nine patients with spontaneous migraine
attack. This brain stem activation included the dorsal
raphe nucleus and the locus coeruleus. This activation
even persisted after successful treatment of the headache
with sumatriptan. The authors concluded that the brain
stem plays a key role in migraine pathophysiology and
over the years this activation spot was named the migraine
‘generator’. In compliance with the strong clinical simi-
larity described above, GTN-triggered delayed headache
is also associated with brain stem activation [12], sup-
porting the hypothesis that the delayed headache after
GTN-infusion is indeed a pure migraine attack. In recent
years, the Copenhagen group investigated several other
substances which showed a similar behaviour [13].
Otherwise there are also a number of substances, which
also induce headache in migraineurs, however, without
fulﬁlling the ICHD-II criteria for migraine as shown for
carbachol [14].
Cluster headache It has been known for more than
40 years that sublingual GTN can trigger cluster headache
attacks within 30–50 min, when given in a cluster period,
whereas it cannot trigger attacks when given outside the
period [15]. Clinically, the attacks were identical to the
spontaneous attacks of the patients. In one case series,
long-acting nitrates, such as isosorbide mononitrate, were
even able to convert cluster patients from out of bout to in
bout [16]. Neuroimaging studies in GTN-induced cluster
headache attacks were able to reveal activations in central
nervous system areas (hypothalamus), pointing to a rele-
vant structure in the genesis of cluster headache [17].
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that GTN is also capable of inducing headache attacks in
patients with tension-type headache (TTH) that resembles
the spontaneous TTH attacks [18].
Taken together, GTN is able to induce typical headache
attacks in patients depending on their individual headache
history. The phenotype of these attacks is clinically indis-
tinguishable from spontaneous attacks and includes, for
migraine, even premonitory symptoms [8]. Further, also
speciﬁcally for migraine, GTN-triggered headache attacks
show the same treatment response to triptans [19]. One of
the impressive characteristics of migraine is its suscepti-
bility to triggers, such as weather changes, meal skipping,
sleep irregularities, alcohol and others. Adding GTN and
its active compound NO to this trigger list therefore seems
to be a mandatory conclusion. Further, triggering headache
with GTN should be regarded as a property that is inherent
for primary headaches and not for one unique secondary
headache. At least for migraine and cluster headache, the
secondary headache ‘delayed headache after GTN-infu-
sion’ might be better listed as ‘GTN-triggered primary
headache attack’. The situation might be similar for
migraine attacks triggered by other substances, whereas
substances like carbachol may cause headaches of an
unspeciﬁc phenotype.
Immune modulation for multiple sclerosis
In addition to such direct time-dependent triggering of a
headache attack by a substance, a more general reduction
of headache threshold in pre-disposed patients is con-
ceivable. Pollmann et al. [20] studied 65 patients beginning
therapy with interferon beta for multiple sclerosis. During
therapy, headache frequency and duration increased by at
least 50 % in 18 % of all patients in comparison to 35 %
of the patients with pre-existing headache. A ‘‘new’’
headache in patients without history of headache occurred
in nine patients (17 %). Five of these had headache trig-
gered by the injection and in seven, headache was either
migraine-like or TTH-like. This suggests that interferon
beta (i) might increase the likelihood of headache attacks
in pre-disposed patients, (ii) might trigger headache
attacks in patients with primary headaches and (iii) might
be able to start a primary headache-like syndrome in
patients without prior history of headache. Such an
increase in headache has not been demonstrated for gla-
tiramer acetate [21], underlining the theory that it is a
speciﬁc effect of interferon beta which is causal for the
increased headache frequency. In contrast to glatiramer
acetate interferon beta activates NF-Kappa-B dependent
pathways which may result in an increased production of
nitric oxide [22].
Headache in patients with epilepsy
The IHS recognises post-ictal headache (ICHD-II 7.6.2)
when it occurs within 3 h following a generalised or focal
epileptic seizure [1]. Schon et al. [23] reported 100 patients
with epilepsy, 51 of whom had post-ictal headache (51 %).
Of the patients with epilepsy and history of migraine
(n = 9), eight (89 %) had post-ictal headache with typical
features for their individual migraine history. Of the
remaining 43 patients with post-ictal headache but without
migraine history, 29 had at least photophobia or vomiting
in addition to their headache. In the majority, pain wors-
ened with movement and improved with sleep. Patients
with a history of migraine and epilepsy thus seem to be at
risk for migraine-like post-ictal headache. Family history
was not assessed in this study. The migraine-like post-ictal
headache of patients without history of migraine could not
be explained by the design of this study. Theoretically,
there might be two main reasons for it: (i) The comorbidity
of migraine and epilepsy [24] and especially the high
prevalence of migraine in patients with epilepsy [25] might
point to a shared pathophysiological mechanism. (ii)
Migraine is a common disease and thus, patients with
post-ictal headache might have a genetic background of
headache.
In 110 patients with epilepsy presented by Forderreuther
et al. [26], post-ictal headache (n = 46) represented by far
the most common seizure-associated headache (n = 47). In
68 % of the patients with seizure-associated headache, the
phenotype corresponded to a primary headache (migraine-
like in 34 % and TTH-like in another 34 %). Patients with
a migraine-like headache also responded to triptans in such
situations [27]. The Headache in Epileptic Patients (HELP)
Study Group has further looked into the characteristics of
seizure-related headache. 24.5 % of 597 patients with
epilepsy had post-ictal headache, which was moderate to
severe (mean 6.3 on the visual rating scale) and lasted
9.0 ± 17.4 h. 36.3 % of all patients had migraine-like
headache. In contrast, 61.5 % of patients with further his-
tory of migraine had migraine-like post-ictal headache.
Thus, it should be noted that post-ictal headache (i) is
signiﬁcantly more likely in patients with migraine in the
past and (ii) is migraine-like in most patients with and a
great proportion of patients without migraine history.
Cortical spreading depression (CSD) is thought to be
important for the mechanism of migraine, especially for the
aura in migraine with aura [28]. Patients with juvenile
myoclonic epilepsy have a signiﬁcantly higher risk (RR
7.3) of also suffering from migraine with aura [25]. This
might be related to a reduced threshold for triggering CSD
in patients with epilepsy in comparison to patients without
epilepsy. This might indicate a more general change in
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foci might further be the starting-point of CSD, resulting in
the migraine-like ‘secondary’ headache—or, in other
words, a ‘true’ migraine attack in patients with migraine,
triggered by an epileptic seizure. The relevance of such a
mechanism was demonstrated in a patient with photosen-
sitive occipital lobe epilepsy, who had a non-convulsive
status epilepticus manifesting solely with status migraino-
sus and, in the interval, migraine attacks being triggered by
intermittent photic stimulation [30]. According to the
ICHD-II criteria, such ictal epileptic headache usually lasts
seconds to minutes (hemicrania epileptica, ICHD-II 7.6.1)
and has migrainous features. This suggests that the head-
ache stops with the end of the seizure. However, there is no
obvious reason why an ictal epileptic headache should
not continue as a migraine attack in susceptible patients.
Chronology-wise most patients might have some degree of
amnesia during the epileptic seizure lasting a further few
minutes beyond the end of the seizure. Patients thus might
not notice or forget headaches during the seizure and in the
ﬁrst minutes after the seizure. A further confounding factor
might be that patients and witnesses might miss the head-
ache because they are overwhelmed by the dramatic
manifestation of a seizure.
Post-ictal headache therefore might, in most cases, be a
migraine attack triggered by an epileptic seizure.
Headache in patients with brain tumours
Headache can be a symptom of intracranial neoplasms—a
brain tumour actually represents one of the main fears of
patients with troublesome headaches. Irrespective of ame-
lioration by treatment, its prevalence ranges from 48 to
71 % of the patients [31–33]. More than 90 % of the
patients have at least one neurological symptom in addition
to the headache: In a retrospective study of 92 patients with
malignant glioma, 48 patients had headache but only two
of those (4 %) had no further neurological or neuropsy-
chological deﬁcit. Similarly, only 15 of 183 (8 %) [34] and
one of 85 (2 %) brain tumour patients had headache as the
sole symptom leading to the diagnosis [32].
Although the pathophysiology of tumour headache is
still unknown, the ICHD-II suggests that two mechanisms
are responsible for its development. These are an ‘elevation
of intracranial pressure’ (ICP, coded as ICHD-II 7.4.1) or a
‘direct tumour inﬂuence’ (ICHD-II 7.4.2) [1]. ‘Elevated
ICP’ should either be deﬁned radiologically by the dem-
onstration of a space-occupying tumour causing hydro-
cephalus or clinically by the presence of nausea or by
aggravation due to manoeuvres known to increase ICP (e.g.
lying ﬂat, Valsalva manoeuvre, etc.). This ‘elevated ICP’
is contrasted with ‘direct tumour inﬂuence’, which, how-
ever, was only deﬁned by its clinical manifestation by
aggravation during horizontal posture (i.e. worsening in the
morning) or when bending forward or coughing. Since
these aggravating factors are associated with an increase of
ICP, the differentiation between ICHD-II 7.4.1 and ICHD-
II 7.4.2 seems to be obsolete due to the identical mecha-
nism ‘elevated ICP’.
Only a minority of patients (17–23 % in Forsyth [31]
and 23 % in Schankin [32]) showed these classical features
of early morning headache or worsening with Valsalva
manoeuvres. In contrast, a study of 85 unselected patients
with primary and secondary headache demonstrated a
TTH-like featureless headache in 20 patients (39 %) [32].
Similarly, tumour-associated headache was found in 23 of
58 patients with meningioma (40 %). The headache was
TTH-like in 13 (56 %) and migraine-like in ﬁve (22 %)
patients [35]. Valentinis et al. [36] found tumour-attributed
headache in 47.6 % of 206 patients with unselected
tumours. Of those, 23.5 % fulﬁlled the criteria for TTH and
13.3 % the criteria for episodic migraine without aura,
whereas only 5.1 % had the classical criteria for intracra-
nial tumour headache. The similarity to primary headaches
is even higher for pituitary adenomas. Levy et al. [37]
found in a case series of 84 patients with pituitary adenoma
and headache that 76 % had migraine, 27 % had primary
stabbing headache (in all but 1 patient, i.e. 1 %, primary
stabbing headache occurred together with other headache
diagnoses), 5 % had short-lasting unilateral neuralgiform
headache with conjunctival injection and tearing (SUNCT),
4 % had cluster headache and 1 % had hemicrania con-
tinua. The headache in 11 patients (13 %) could not be
classiﬁed using the ICHD-II criteria for primary headaches.
In addition to this primary headache-like phenotype in a
great proportion of patients with tumour headache, the
history or family history of primary headaches is a risk
factor for the occurrence of headache in association with
unselected brain tumours [31, 32, 36], meningioma [35]o r
pituitary adenoma [37, 38].
Taken together, these two ﬁndings, similar phenotype
and higher prevalence in pre-disposed patients, point to a
shared pathophysiological mechanism of tumour-associ-
ated headache and primary headaches. Besides central
sensitization, the activation of trigeminal meningeal affer-
ents is thought to be involved in the pathophysiology of
headache [39]. Possible connections between primary and
secondary headaches might be the thresholds and mecha-
nisms by which trigeminal ﬁbres of the meninges are
activated. In patients with a predisposition towards head-
ache (i.e. primary headache in the past), the tumour might
act as an unspeciﬁc trigger of these primary headache
mechanisms. This model could further explain why the
tumour-attributed headache is often similar to the primary
headache syndrome. However, it does not explain why
patients with no positive history of headache develop
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notypes cannot be classiﬁed as a primary headache-like
headache. Alternatively or in addition, the tumour itself
might be responsible for both predisposition and trigger.
Mechanisms, which predispose towards or trigger
tumour-attributed headache could be local tumour effects.
The most obvious factor, namely, tumour size, could not be
conﬁrmed in most studies when looking at brain tumours in
general [32, 40], meningioma [35] or pituitary adenoma
[38, 41], although Gondim et al. [42] and Valentinis et al.
[36] demonstrated some dependence of headache on
tumour size. For meningioma, bone-invasive growth pat-
tern was signiﬁcantly associated with tumour headache
(odds ratio 4.5) [35].
Due to the nature of the tumour, systemic endocrine
factors have been discussed, especially for pituitary adeno-
mas. Some case reports on headache in patients with a pro-
lactinoma [43–46] or patients with acromegaly [44, 47–49]
have demonstrated coexistence of or even a causal rela-
tionship between the adenoma and the headache. So far,
however, no prospective clinical study has been able to
conﬁrmsuchacorrelation.AstudybyBoscoetal.[50]found
an elevation of prolactin levels in patients with pituitary
microadenomaduringmigraine-likeheadacheattacks.Since
this study did not include a control group without adenoma,
the relevance of such elevations remains unknown.
Similar to a systemic endocrine mechanism, local par-
acrine mechanisms have also been discussed. A patient
with an intracranial metastasis of a thyroid carcinoma has
been reported who experienced a recurrence of migraine
attacks after freedom from any headaches for about
30 years, suggesting that the metastasis triggered migraine
attacks by mechanisms that were similar to ‘primary’
migraine attacks [51]. A tumour might have direct contact
to meningeal structures. Substances produced by the
tumour therefore might inﬂuence the function of the tri-
geminal nerve endings, possibly resulting in a headache
sensation in the patient. Further, the different phenotypes
of the tumour headache (i.e. migraine-like or TTH-like)
might be determined, at least in part, not only by the
genetic background of the patient but also by the tumour
expression proﬁle. Immunohistochemical techniques have
been used to compare the expression of signal substances
with a putative role in headache pathophysiology (CGRP,
substance P, neuropeptide Y, VIP) in tumour tissue in
patients with and without pituitary adenoma-associated
headache. These studies were not able to show a stable
correlation with the occurrence of headache [52–54].
Although Schankin et al. [35] could demonstrate the
expression of various signal substances with relevance for
headache pathophysiology in meningioma tissue, no sig-
niﬁcant correlation was found for the occurrence of tumour
headache.
In summary, tumour headache is frequent, resembles
primary headaches in a great proportion of patients and is
found more often in patients with pre-existing headache
history. This suggests an overlap of mechanisms for pri-
mary and secondary headaches. In the case of tumour
headache, these mechanisms might be mechanical or local
paracrine processes.
Post-craniotomy headache
The IHS deﬁnes post-craniotomy headache (ICHD-II 5.7)
as (i) occurring in the area of the surgery and (ii) devel-
oping within 7 days after craniotomy, which was per-
formed, for non-traumatic head pathology. Its prevalence
varies and depends on the type of surgery, but can exceed
40 % [55, 56]. A post-craniotomy headache, which is
severe and lasts longer than 6 months, has been found in 30
of 95 patients (32 %) who were operated on for acoustic
neurinoma [57]. Its prevalence has been shown to depend
on the time interval between surgery and survey with a
decrease over time [58, 59]. For acoustic neuroma surgery,
Schessel et al. [60] have demonstrated that 63.7 % of
patients operated on using the suboccipital approach report
signiﬁcant postoperative headache, whereas such headache
was present only in a small subgroup of patients operated
on using the translabyrinthine technique. In respect of
headache phenotype, the ICHD-II requires that headache
occurs in the area of the surgery [1]. Gee et al. [61] have
retrospectively analysed the data of 102 unselected patients
with craniotomy and found that 55 % of the patients with
headache had pain over the surgical side. However, in
36 % of the patients the headache was TTH-like and 18 %
had migrainous features, such as severe intensity, throbbing
quality and association with nausea and vomiting. A study
on patients after suboccipital surgery for acoustic neuroma
attempted to characterise postcraniotomy headache
according to ICHD-II [57]. The most frequent headache
phenotype was TTH-like (46.7 %), whereas the local pain
syndromes [i.e. neuralgia of the occipital nerve (16.6 %),
trigeminal neuropathy (16.6 %), neuropathy of the inter-
median nerve (10.0 %) and cervicogenic headache
(10.0 %)] were less common. The authors further showed a
signiﬁcant correlation between a pre-existing headache
syndrome and post-craniotomy headache. Gee et al. [61]
demonstrated similarly that a higher proportion of patients
with pre-existing headache had postcraniotomy headache
(28/44) in contrast to only 11/58 without pre-existing
headache.
Thus, although many patients fulﬁl the criterion of pain
in the surgical area, a signiﬁcant number suffer from a
headache with a primary headache-like phenotype, which
is more likely to occur in patients with a history of
headache.
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The ICHD-II distinguishes between primary and secondary
headaches. In order to make the diagnosis, the clinician
should decide whether a pure secondary headache or both a
primary and secondary headache is present. The possibility
that the secondary headache actually represents a variation
of the primary headache is not considered.
The effect of GTN on primary headaches teaches us that
some secondary headaches actually only represent trig-
gered primary headaches. The fact that various conditions,
events or substances (such as sleep deprivation, skipping
meals, menstrual period, weather changes and GTN) can
trigger headache attacks is a property of migraine. It does
not mean that one of the triggers (in this case GTN) can be
treated differently from the other triggers by allocating the
term ‘secondary headache’ to the one and ‘primary head-
ache’ to the other. For interferon beta, this is clearly more
complicated since it not only seems to trigger headache but
also might reduce the threshold for other triggers. Future
studies are necessary to elucidate the mechanism of inter-
feron beta in respect of migraine headache.
Similarly, post-ictal headache is more frequent in
patients with primary headaches or in patients with rela-
tives who have a primary headache. Further, the phenotype
of the headache is almost identical to a pre-existing pri-
mary headache. Combining these clinical ﬁndings with
pathophysiological similarities between CSD as proposed
trigger for migraine and epileptic foci suggests that epi-
leptic seizures actually trigger ‘true’ migraine attacks.
For brain tumour headaches, the ICHD-II lists ‘elevation
of ICP’ or ‘direct tumour inﬂuence’ as possible mecha-
nisms, although a closer look identiﬁes ‘direct tumour
inﬂuence’ as also being mediated by an increase of ICP. In
contrast, only a minority of patients exhibit clinical signs of
increased ICP, whereas a primary headache-like phenotype
is far more likely. Thus, headache attributed to brain
tumours might also be an activation of a primary headache
in some patients (e.g. by triggering a CSD-like phenome-
non in the vicinity of the tumour) and there might even be
some pathophysiological overlap. However, in contrast to
GTN or epileptic seizures, the sine qua non of tumour
headache is the brain tumour. Therefore, claiming that
brain tumour-associated headache is only a primary head-
ache that is triggered by the tumour would be impudent.
Nevertheless, the close similarity to primary headaches
makes it obsolete to list brain tumour-attributed headache
as a pure secondary headache with the only mechanism
being ‘elevated ICP’.
Similarly to the other selected headache syndromes,
post-craniotomy headache is more frequent in patients with
a history of primary headache and its phenotype is pre-
vailing TTH- or migraine-like. The local pain syndromes
are less common but currently represent a key diagnostic
criterion for post-craniotomy headache in the ICHD-II.
Therefore, it would be better to differentiate between two
kinds of post-craniotomy headache, namely, triggering of
primary headaches and injury of local pain-sensitive
structures. As for brain tumour-attributed headache, listing
post-craniotomy headache as a pure secondary headache
would not do justice to the primary headache-like clinical
presentation.
That the differentiation between ‘pure’ secondary head-
aches and ‘triggered primary’ headaches might be more
than just an academic dispute is probably shown by the
ﬁnding that pre-treatment with a beta blocker, a typical
migraine prophylactic, seems to be protective against the
occurrence of headaches in patients with brain tumour [32].
Clearly, it has to be investigated in further studies whether
drugs used in primary headache prophylaxis also have a
prophylactic effect for secondary headaches. This may be a
ﬁrst indication of therapeutic consequences of such a dif-
ferentiation between secondary headaches and ‘triggered’
primary headaches.
Conclusion
The International Classiﬁcation of Headache Disorders
distinguishes between primary and secondary headaches
based on whether a causative disorder for the headache can
be demonstrated. This has proven great practicality and
was an important step in the understanding of headache.
The intention of our review was to show that there is
increasing knowledge on how secondary headaches clini-
cally overlap with primary headaches and how they might
develop. We wanted to contribute to the still open question
whether the headache in some secondary headaches might
be caused by neurobiological mechanisms, which are
similar to those of primary headaches.
The consequences of these observations are as follows:
1. Some selected secondary headaches have a close
relationship to pre-existing primary headaches.
2. However, clearly not all secondary headaches are
triggered primary headaches. Subarachnoidal haemor-
rhage and meningitis, for example, have a clinical
presentation including a pain phenotype that is mark-
edly different from migraine or TTH.
3. Secondary headaches presenting as variations of
primary headaches have the phenotype of primary
headaches and should be treated by (i) avoidance of
the trigger, i.e. treatment of the underlying disease, by
(ii) treating the phenotype, e.g. using triptans for
migraine-like headaches, and probably (iii) using the
same prophylaxis as for primary headaches.
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1234. Patients with a history of headache but atypical
presentation in the course should be evaluated for
treatable triggers, i.e. an underlying disease.
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